Heart Failure NYHA Class IV, Heart Failure NYHA Class II
Conditions
Keywords
chronickindeydisease, qualityoflife
Brief summary
The two primary goals of it's management are preventing further disease progression(mortality,hospitalizations and deterioration of left ventricular function)and alleviating patient suffering
Detailed description
Heart failure (HF) is emerging as an epidemic in 3rd world countries. Despite significant therapeutic advances, patients with chronic heart failure remain at high risk for HF progression and death. The two primary goals of its management are preventing further disease progression(mortality, hospitalizations and deterioration of left ventricular function)and alleviating patient suffering.Sacubitril /valsartan (previously known as LCZ696) is a first-in-class medicine that contains a neprilysin (NEP )inhibitor(sacubitril) and an angiotensin II receptor blocker (valsartan). NEP is an endopeptidase that metabolizes different vasoactive peptides including natriuretic peptides, bradykinin and Ang -II. In consequence, its inhibition increases mainly the levels of both natriuretic peptides (promoting diuresis, natriuresis and vasodilation) and Ang- II whose effects are blocked by the angiotensin receptor blocker, valsartan (reducing vasoconstriction and aldosterone release).
Interventions
Sacubitril/Valsartan is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction. Sacubitril/Valsartan is usually administered in conjunction with another heart failure therapies, in place of an ACE inhibitor or other ARB.
Sponsors
Clinision
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Inclusion criteria
1. Patients with heart failure (NYHA class II-IV). 2. LV EF(less than or equal to 40%). 3. eGFR (more than 30 ml/min /1.73m2).
Exclusion criteria
1. Symptomatic hypotension. 2. eGFR\<30 ml/min/1.73m2 . 3. Serum potassium \>5.2mmol/L 4. Angioedema
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assess the result on the quality of life through Kansas city cardiomyopathy Questionnaire | 1 year | comparison of the quality of life questionnaire before and after the treatment of sacubitril/ valsartan |
| Analyze the result on mortality of heart failure patients through Kansas city cardiomyopathy Questionnaire | 1 year | Improvement in mortality of heart failure patients after taking treatment of sacubitril/ valsartan. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of acute kidney injury after taking angiotensin receptor neprilysin inhibitor | 1 year | changes in the baseline of acute kidney injury, electrolyte imbalance and hemodynamic instability before and after taking treatment of sacubitril valsartan |
Countries
Pakistan
Outcome results
None listed